Data released from the second cohort of the ABX-464-005 trial indicates that ABX-464 can reduce the latent HIV reservoir in gut as well as in peripheral blood in patients receiving anti-retroviral therapy. Compared to the first trial cohort, these data suggest that the drug is safe when used over a longer period (3 months vs. 28 days) and has an impact on multiple latent viral reservoirs in HIV-infected patients; even when u sed at a third of the dose (50mg/day vs. 150mg/day). While full data from the trial is not expected until late Q3 / early Q4 2018E, these preliminary data should be seen as encouraging, suggesting that the trial should form a strong platform for movement into a Phase 2b study. We reiterate our OUTPERFORM recommendation and €19.50 target price.
03 Jul 2018
ABX464 reduces HIV DNA in latent viral gut reservoir
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
ABX464 reduces HIV DNA in latent viral gut reservoir
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
03 Jul 2018 -
Author:
GOETZPARTNERS CORPORATE RESEARCH Research Team -
Pages:
5
Data released from the second cohort of the ABX-464-005 trial indicates that ABX-464 can reduce the latent HIV reservoir in gut as well as in peripheral blood in patients receiving anti-retroviral therapy. Compared to the first trial cohort, these data suggest that the drug is safe when used over a longer period (3 months vs. 28 days) and has an impact on multiple latent viral reservoirs in HIV-infected patients; even when u sed at a third of the dose (50mg/day vs. 150mg/day). While full data from the trial is not expected until late Q3 / early Q4 2018E, these preliminary data should be seen as encouraging, suggesting that the trial should form a strong platform for movement into a Phase 2b study. We reiterate our OUTPERFORM recommendation and €19.50 target price.